Free tool
FAERS Monitor: Cancidas
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021227 or its brand name (Cancidas, Caspofungin Acetate). Reports on generic versions are filed under their own applications.
Reports
4,741
Serious
4,443
94% of reports
Hospitalization
2,047
Death reported
1,687
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective684
- off label use252
- death226
- product use in unapproved indication210
- pneumonia203
- pyrexia197
- septic shock197
- sepsis192
- febrile neutropenia170
- multiple organ dysfunction syndrome151
- respiratory failure131
- renal failure129
- drug interaction125
- fungal infection124
- acute kidney injury122
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 157 |
| 2005 | 138 |
| 2006 | 129 |
| 2007 | 170 |
| 2008 | 143 |
| 2009 | 146 |
| 2010 | 142 |
| 2011 | 186 |
| 2012 | 177 |
| 2013 | 171 |
| 2014 | 221 |
| 2015 | 249 |
| 2016 | 258 |
| 2017 | 314 |
| 2018 | 359 |
| 2019 | 364 |
| 2020 | 282 |
| 2021 | 213 |
| 2022 | 205 |
| 2023 | 187 |
| 2024 | 220 |
| 2025 | 181 |
| 2026 | 129 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,418 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| multiple organ dysfunction syndromeSignal | 151 | 23.8 | 20.3 | 3,258 |
| septic shockSignal | 197 | 20.2 | 17.6 | 3,562 |
| fungal infectionSignal | 124 | 16.6 | 13.9 | 1,794 |
| febrile neutropeniaSignal | 170 | 11.4 | 9.8 | 1,603 |
| respiratory failureSignal | 131 | 8.0 | 6.7 | 794 |
| sepsisSignal | 192 | 7.6 | 6.7 | 1,107 |
| renal failureSignal | 129 | 4.3 | 3.6 | 327 |
| product use in unapproved indicationSignal | 210 | 3.8 | 3.3 | 428 |
| acute kidney injurySignal | 122 | 3.5 | 3.0 | 221 |
| drug interactionSignal | 125 | 3.5 | 2.9 | 222 |
| pneumoniaSignal | 203 | 2.8 | 2.4 | 234 |
| pyrexiaSignal | 197 | 2.5 | 2.2 | 183 |
| drug ineffectiveSignal | 684 | 2.3 | 2.1 | 536 |
| off label use | 252 | 1.3 | 1.1 | 15 |
| death | 226 | 1.2 | 1.0 | 5 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.